Curasight är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av teknologiska produkter. Produktportföljen har sitt huvudsakliga fokus inom utvecklingen av innovativa teknologier för diagnostik och behandling av cancer baserat på målstyrd PET-avbildning och radionuklidterapi. Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.
Curasight announced this morning that it has completed a directed issue of approximately DKK 20m before transaction costs. The issue extends the company's financing horizon. Management now assesses that the net proceeds are sufficient to fund operations through the end of H1 2027.
Curasight this morning announced an encouraging preliminary readout from its Phase 1 trial with uTREAT® in glioblastoma (GBM), This the first of the four high-value data read-outs management guided to for the coming six months.
In connection with Curasight's Q1 2026 interim report, we have updated our Investment Case. Our investment case covers the key investment reasons, risks, and valuation perspectives.
In connection with the annual report, we have updated our Investment Case One-pager for Curasight.
2025 marked a defining transition for the company — from building and validating its uPAR platform to actively advancing its therapeutic program uTREAT into the clinic. The highlight of the year was the dosing of the first patient in the Phase 1 glioblastoma trial in December, marking the initiation of Curasight's first-ever clinical trial under its therapeutic platform. Combined with a strengthened capital base and continued progress on the diagnostic platform uTRACE, the company enters 2026 as an active clinical-stage radioligand therapy developer with two significant data readouts on the horizon.
